Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Stephen Michael Kelsey reported a proposed/recorded sale of 5,447 shares of Common Stock on 12/16/2025 for $418,423.29. The filing also lists restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025 with counts 910, 937, 1,193, and 861, respectively.
Margaret A. Horn filed a Form 144 reporting sales of Common Stock. The filing lists a sale of $372,333.45 for 4,847 shares on 12/16/2025 and a sale of $7,542,022.50 for 75,000 shares on 01/07/2026. The excerpt also lists restricted stock unit grants dated 03/01/2022 (1,234 units), 03/01/2023 (1,273 units), 03/01/2024 (1,305 units) and 03/01/2025 (910 units).
Revolution Medicines reported insider sales of Common Stock by Mark A. Goldsmith. The filing lists a sale of 15,394 shares on 12/16/2025 for $1,182,525.52 and three sales on 03/02/2026 of 3,000 shares for $303,792.60, 3,000 shares for $303,984.90, and 30,000 shares for $3,036,576.00.
The filing also lists restricted stock unit grants dated 03/01/2022 (3,488 shares), 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,267 shares) under issuer grants.
Revolution Medicines: Form 144 notice of proposed resale of Common Stock by an affiliate. The filing lists past sales by Jeff Cislini of $206,483.83 for 2,688 shares on 12/16/2025 and $104,964.80 for 908 shares on 01/21/2026. The record also lists historic restricted stock unit grants of 219, 222, 548, 521, and 543 shares on various grant dates; these grant counts are shown as award history.
Revolution Medicines insider sale reported. The filing lists sales by Jack Anders of 3,104 shares on 12/16/2025 and 10,000 shares on 01/07/2026, with reported proceeds of $239,288.60 and $980,000.00 respectively.
The notice also lists historical restricted stock unit grants with grant dates of 03/01/2022, 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, showing grant quantities of 261, 225, 597, 593, and 458 shares.
Revolution Medicines, Inc. director Elizabeth M. Anderson reported two bona fide gifts of common stock totaling 30,000 shares. The gifts, coded as "G" transactions, occurred on March 4, 2026 at a reported price of $0.00 per share, indicating non-cash charitable or personal transfers.
After these transactions, Anderson holds 8,215 shares directly and 26,990 shares indirectly. The indirect holdings include 3,142 restricted stock units and shares held by trusts, including the Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson and the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026. Wang was granted stock options for 34,000 shares at an exercise price of $0.00 and 15,100 shares of common stock, both as awards rather than open-market purchases.
Following the common stock grant, Wang directly owned 118,073 common shares, which includes 54,464 restricted stock units and 652 shares acquired under the employee stock purchase plan. The option award vests in equal monthly installments over four years starting March 1, 2026, contingent on continued service.
Revolution Medicines Chief Medical Officer Wei Lin reported equity awards that increase his stake in the company. He received a stock option for 34,000 shares at an exercise price of $0.00 per share and a direct grant of 15,100 shares of common stock.
After these awards, Lin directly holds 103,439 shares of common stock, which includes 68,000 restricted stock units. The option vests in equal monthly installments over four years starting on March 1, 2026, contingent on his continued service with the company.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings. He received a stock option covering 47,600 shares of common stock at an exercise price of $0.00 per share, characterized as a grant or award acquisition. He also acquired 21,100 shares of common stock as a separate grant, bringing his directly held common shares to 299,700, which includes 94,676 restricted stock units. The option vests in equal monthly installments over four years starting March 1, 2026, with one forty-eighth of the shares vesting each month so that all option shares are fully vested on the fourth anniversary, contingent on his continued service.
Revolution Medicines director and officer Mark A. Goldsmith reported option grants, share awards, option exercises and planned sales in RVMD stock. On March 1, 2026, he received stock options for 128,600 shares and 57,100 shares of common stock as grants, with the options vesting monthly over four years starting March 1, 2026.
On March 2, 2026, he exercised 30,000 stock options and acquired 30,000 common shares, then related accounts sold a total of 36,000 common shares in multiple open‑market trades around $98–$102 per share, including sales by family trusts under a Rule 10b5‑1 trading plan. After these transactions, he held 318,869 common shares directly plus additional shares indirectly through trusts, including 225,863 restricted stock units.